ERBB2 and non-small cell lung carcinoma: The subsequent DESTINY-Lung01 trial confirmed that T-DXd induces durable responses in previously treated patients with HER2-mutant NSCLC, and 55% of patients refractory to prior standard treatment had an objective response lasting for a median of 9.3 months.